Bellevue Group’s Q32 Bio QTTB Stock Holding History

Bellevue Group’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-90,140	Closed	-$2.04M	–	174
2022 Q4	$2.04M	Hold	90,140	–	–	0.03%	125
2022 Q3	$2.61M	Hold	90,140	–	–	0.04%	118
2022 Q2	$3.2M	Sell	90,140 -1,367	-1%	-$46.7K	0.05%	117
2022 Q1	$5.01M	Sell	91,507 -5,000	-5%	-$311K	0.06%	115
2021 Q4	$6.32M	Hold	96,507	–	–	0.07%	119
2021 Q3	$13.7M	Hold	96,507	–	–	0.14%	106
2021 Q2	$12.6M	Hold	96,507	–	–	0.12%	121
2021 Q1	$16.3M	Hold	96,507	–	–	0.17%	107
2020 Q4	$19.6M	Hold	96,507	–	–	0.22%	101
2020 Q3	$18.6M	Hold	96,507	–	–	0.26%	92
2020 Q2	$26.4M	Buy	96,507 +6,945	+8%	+$1.85M	0.37%	66
2020 Q1	$25.1M	Hold	89,562	–	–	0.49%	53
2019 Q4	$33.4M	Hold	89,562	–	–	0.53%	48
2019 Q3	$29.2M	Buy	89,562 +11,666	+15%	+$3.97M	0.54%	47
2019 Q2	$27.4M	Buy	+77,896	New	+$30.6M	0.47%	51

Other funds holding QTTB

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Bellevue Group's QTTB Position: Q1 2023 in Review

Bellevue Group sold out of Q32 Bio (QTTB) in Q1 2023, closing a stake of 90,140 shares — an estimated $2.04M sold.

Bellevue Group first reported a position in QTTB in Q2 2019 and held it in 15 quarters. The position peaked at $33.4M in Q4 2019. 62 funds tracked by Wall St. Rank hold QTTB as of Q1 2023.

Bellevue Group reported no remaining Q32 Bio position as of Q1 2023 after selling out during the quarter.
Bellevue Group sold 90,140 Q32 Bio shares in Q1 2023, an estimated $2.04M.
Bellevue Group first reported a position in Q32 Bio in Q2 2019 and held it in 15 quarters.
Bellevue Group's Q32 Bio position peaked at $33.4M in Q4 2019.
62 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2023.

Based on Bellevue Group's 13F filing for Q1 2023, filed 15 May 2023.